Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W C Lumma

Showing results (11-20 of 36) with videos related to

Pageof 4
Sort By:
Journal of Medicinal Chemistry|March 2, 1992
Synthesis, cardiac electrophysiology, and beta-blocking activity of novel arylpiperazines with potential as class II/III antiarrhythmic agentsG B Phillips, T K Morgan, W C Lumma, et al.
Journal of Medicinal Chemistry|June 1, 1978
Piperazinylpyrazines with central serotoninmimetic activityW C Lumma, R D Hartman, W S Saari, et al.
Journal of Medicinal Chemistry|November 1, 1979
Symbiotic approach to drug design: antihypertensive beta-adrenergic blocking agentsJ J Baldwin, W C Lumma, G F Lundell, et al.
Journal of Medicinal Chemistry|April 1, 1987
Synthesis and antiarrhythmic activity of novel 3-alkyl-1-[omega-[4-[(alkylsulfonyl)amino]phenyl]-omega- hydroxyalkyl]-1H-imidazolium salts and related compoundsR Lis, T K Morgan, R J DeVita, et al.
Journal of Medicinal Chemistry|March 14, 1997
Design of highly potent noncovalent thrombin inhibitors that utilize a novel lipophilic binding pocket in the thrombin active siteT J Tucker, W C Lumma, A M Mulichak, et al.
Journal of Medicinal Chemistry|February 1, 1983
Conformational requirements for histamine H2-receptor inhibitors: a structure-activity study of phenylene analogues related to cimetidine and tiotidineJ M Hoffman, A M Pietruszkiewicz, C N Habecker, et al.
Journal of Medicinal Chemistry|August 1, 1987
Cardiotonic agents. 2. (Imidazolyl)aroylimidazolones, highly potent and selective positive inotropic agentsA A Hagedorn, P W Erhardt, W C Lumma, et al.
Journal of Medicinal Chemistry|April 17, 1998
Design of novel, potent, noncovalent inhibitors of thrombin with nonbasic P-1 substructures: rapid structure-activity studies by solid-phase synthesisW C Lumma, K M Witherup, T J Tucker, et al.
Journal of Medicinal Chemistry|April 1, 1990
Synthesis and pharmacological studies of N-[4-[2-hydroxy-3-[[2-[4-(1H-imidazol-1- yl)phenoxy]ethyl]amino]propoxy]phenyl]methanesulfonamide, a novel antiarrhythmic agent with class II and class III activitiesT K Morgan, R Lis, W C Lumma, et al.
Journal of Medicinal Chemistry|April 1, 1990
Synthesis and cardiac electrophysiological activity of N-substituted-4-(1H-imidazol-1-yl)benzamides--new selective class III agentsT K Morgan, R Lis, W C Lumma, et al.
Pageof 4

Showing results (11-20 of 36) with videos related to

Sort By:
Pageof 4
Journal of Medicinal Chemistry|March 2, 1992
Synthesis, cardiac electrophysiology, and beta-blocking activity of novel arylpiperazines with potential as class II/III antiarrhythmic agentsG B Phillips, T K Morgan, W C Lumma, et al.
Journal of Medicinal Chemistry|June 1, 1978
Piperazinylpyrazines with central serotoninmimetic activityW C Lumma, R D Hartman, W S Saari, et al.
Journal of Medicinal Chemistry|November 1, 1979
Symbiotic approach to drug design: antihypertensive beta-adrenergic blocking agentsJ J Baldwin, W C Lumma, G F Lundell, et al.
Journal of Medicinal Chemistry|April 1, 1987
Synthesis and antiarrhythmic activity of novel 3-alkyl-1-[omega-[4-[(alkylsulfonyl)amino]phenyl]-omega- hydroxyalkyl]-1H-imidazolium salts and related compoundsR Lis, T K Morgan, R J DeVita, et al.
Journal of Medicinal Chemistry|March 14, 1997
Design of highly potent noncovalent thrombin inhibitors that utilize a novel lipophilic binding pocket in the thrombin active siteT J Tucker, W C Lumma, A M Mulichak, et al.
Journal of Medicinal Chemistry|February 1, 1983
Conformational requirements for histamine H2-receptor inhibitors: a structure-activity study of phenylene analogues related to cimetidine and tiotidineJ M Hoffman, A M Pietruszkiewicz, C N Habecker, et al.
Journal of Medicinal Chemistry|August 1, 1987
Cardiotonic agents. 2. (Imidazolyl)aroylimidazolones, highly potent and selective positive inotropic agentsA A Hagedorn, P W Erhardt, W C Lumma, et al.
Journal of Medicinal Chemistry|April 17, 1998
Design of novel, potent, noncovalent inhibitors of thrombin with nonbasic P-1 substructures: rapid structure-activity studies by solid-phase synthesisW C Lumma, K M Witherup, T J Tucker, et al.
Journal of Medicinal Chemistry|April 1, 1990
Synthesis and pharmacological studies of N-[4-[2-hydroxy-3-[[2-[4-(1H-imidazol-1- yl)phenoxy]ethyl]amino]propoxy]phenyl]methanesulfonamide, a novel antiarrhythmic agent with class II and class III activitiesT K Morgan, R Lis, W C Lumma, et al.
Journal of Medicinal Chemistry|April 1, 1990
Synthesis and cardiac electrophysiological activity of N-substituted-4-(1H-imidazol-1-yl)benzamides--new selective class III agentsT K Morgan, R Lis, W C Lumma, et al.
Pageof 4